These results indicate that romosozumab, a humanized monoclonal antibody targeting sclerostin, increases BMD in patients with osteoporosis by enhancing bone formation and turnover markers while inhibiting bone resorption markers. The gene discussed is SOST; the disease is osteoporosis.